The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection
Open accessAbstract
OBJECTIVE: In the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL/SILGARD) clinical program, 73% of women aged 16-26 were naïve to all vaccine HPV types. In these women, prophylactic administration of the vaccine was highly effective in preventing HPV 6/11/16/18-related cervical disease. Of the remaining women, 15% of had evidence of past infection with one or more vaccine HPV types (seropositive and DNA negative) at the time of enrollment. Here we present an analysis in this group of women to determine the efficacy of the HPV 6/11/16/18 vaccine against new cervical and external anogenital disease related to the same vaccine HPV type which had previously been cleared. Vaccine tolerability in this previously infected population was also assessed. METHODS: 18,174 women were enrolled into 3 clinical studies. The data presented comprise a subset of these subjects (n = 2,617) who were HPV seropositive and DNA negative at enrollment (for >or=1 vaccine type). In each study, subjects were randomized in a 1:1 ratio to receive HPV 6/11/16/18 vaccine or placebo at day 1, month 2 and month 6 (without knowledge of baseline HPV status). Procedures performed for efficacy data evaluation included detailed genital examination, Pap testing, and collection of cervicovaginal and external genital specimens. Analyses of efficacy were carried out in a population stratified by HPV serology and HPV DNA status at enrollment. RESULTS: Subjects were followed for an average of 40 months. Seven subjects in the placebo group developed cervical disease, and eight subjects developed external genital disease related to a vaccine HPV type they had previously encountered. No subject receiving HPV 6/11/16/18 vaccine developed disease to a vaccine HPV type to which they were seropositive and DNA negative at enrolment. CONCLUSIONS: These results suggest that natural HPV infection-elicited antibodies may not provide complete protection over time, however the immune response to the HPV 6/11/16/18 vaccine appears to prevent reinfection or reactivation of disease with vaccine HPV types. Vaccine-related adverse experiences were higher among subjects receiving vaccine, mostly due to increased injection site adverse experiences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Self-citationMolecular biology of human papillomavirus infection and cervical cancer
Doorbar, J. (2006) · Clinical Science · doi:10.1042/cs20050369 · Cited by 1,072
Cited by
A review of clinical trials of human papillomavirus prophylactic vaccines
Schiller, J. T., Castellsagué, X., & Garland, S. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.108 · Cited by 747
Self-citationArbyn, M., Xu, L., Simoens, C., & Martin-Hirsch, P. P. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009069.pub3 · Cited by 621
Muñoz, N., Kjaer, S. K., Sigurdsson, K., Iversen, O.-E., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Brown, D. R., Koutsky, L. A., Tay, E. H., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp534 · Cited by 566
Self-citationHPV vaccines – A review of the first decade
Harper, D. M., & DeMars, L. R. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.04.004 · Cited by 429
Opportunities and challenges for human papillomavirus vaccination in cancer
Roden, R. B. S., & Stern, P. L. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.13 · Cited by 333
Metadata
- Authors
- Olsson, S.-E., Kjaer, S. K., Sigurdsson, K., Iversen, O.-E., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Brown, D. R., Koutsky, L. A., Hseon Tay, E., García, P., Ault, K. A., Garland, S. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Paavonen, J., Lehtinen, J., Steben, M., Bosch, F. X., Dillner, J., Joura, E., Majewski, S., Muñoz, N., Myers, E. R., & Villa, L. L.
- Venue
- Human Vaccines
- Publisher
- Informa UK Limited
- Published
- 2009-10
- Volume
- 5
- Issue
- 10
- Pages
- 696-704
- ISSN
- 1554-8600 (ISSN-L)
- 1554-8619
- OpenAlex
- W2051461779
- Cited by
- 217
- References
- 2
- FWCI
- 13.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. https://app.cochat.ai/papers/10.4161/hv.5.10.9515
- The paper
- Olsson, S.-E., Kjaer, S. K., Sigurdsson, K., Iversen, O.-E., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Brown, D. R., Koutsky, L. A., Hseon Tay, E., García, P., Ault, K. A., Garland, S. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Paavonen, J., Lehtinen, J., Steben, M., . . . Villa, L. L. (2009). Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines. https://doi.org/10.4161/hv.5.10.9515
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.